Edgewise Therapeutics, Inc. (EWTX) stock
Close on Nov 12, 2026Market cap $4.98BP/E 5.6Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $4.98B
- P/E ratio
- 5.6
- Price to sales
- –
- Price to book
- 3.05
- Dividend yield
- –
- Free cash flow yield
- -4.06%
Fundamentals
- Net income
- $1.01B
- EPS, diluted
- $8.19
- Free cash flow
- -$202.28M
- Book value per share
- $13.51
- Diluted shares
- 121M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $47.57
- Open
- $46.46
- Day's range
- $45.04 – $46.93
- Volume
- 1,097,357
- Average volume (20 days)
- 1,734,553
- Index membership
- Russell 2000 (since Jun 2021), Russell 3000 (since May 2021)
- Beta (5 years)
- 1.48
- 52-week range
- $19.76 – $48.78
- RSI (14 days)
- 61.6
- Volatility (1 year)
- 73.2%
- Relative volume
- 0.76×
- WACC
- 12.3%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | EWTX | S&P 500 | Difference | EWTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +19.2% | -2.7% | +21.9 pts | ||
| 3 months | +5.2% | -1.7% | +6.9 pts | ||
| Year to date | +84.6% | +11.9% | +72.8 pts | ||
| 1 year | +116.4% | +12.0% | +104.5 pts | ||
| 3 years | +731.6% | +78.2% | +653.4 pts | +102.6% | +21.2% |
| 5 years | +138.5% | +73.2% | +65.3 pts | +19.0% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Edgewise Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael CarruthersUpdate
About Edgewise Therapeutics
Pharmaceutical Preparations
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision small molecule medicines for severe neuromuscular and cardiac disorders. The company utilizes a proprietary, muscle-focused drug discovery platform that evaluates integrated muscle function in whole organ extracts. Its pipeline features lead candidate sevasemten, an orally administered fast myofiber myosin inhibitor in late-stage clinical trials for Becker muscular dystrophy and Duchenne muscular dystrophy. Edgewise is also developing cardiac sarcomere modulators, including clinical-stage candidate EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for heart failure with preserved ejection fraction, along with preclinical cardiometabolic programs. Its intended customer base comprises patients affected by rare, debilitating skeletal and cardiac muscle conditions with limited or no approved therapies.
Company profile, executives and historyEdgewise Therapeutics stock: common questions
What is Edgewise Therapeutics's stock price?
EWTX closed at $45.82 on Nov 12, 2026, down 3.68% on the day. Over the past 52 weeks it traded between $19.76 and $48.78.
What is Edgewise Therapeutics's market cap?
Edgewise Therapeutics was worth $4.98B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is EWTX's P/E ratio?
EWTX trades at 5.6 times earnings, based on diluted earnings per share of $8.19 over the twelve months to Sep 30, 2026.
Does Edgewise Therapeutics pay a dividend?
No. Edgewise Therapeutics has not paid a cash dividend over the last twelve months.
When does Edgewise Therapeutics report earnings next?
Edgewise Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has EWTX stock performed over the past year?
Including dividends, EWTX returned +116.4% over the past year, against +12.0% for the S&P 500.
How many EWTX shares are sold short?
13M shares were sold short at the latest FINRA report, 14.62% of the float, or 9.6 days of average trading volume.
Who are Edgewise Therapeutics's competitors?
Companies most similar to Edgewise Therapeutics by business, industry and size include CYTK, SRPT, KROS, TRDA, NAMS.
See a number that looks wrong?